EQRx Aims To Upend Industry’s Pricing Model, With Me-Too Drugs
With a $200m series A financing and an illustrious founding team, including Alexis Borisy and Peter Bach, EQRx plans to develop cheap me-too drugs. The start-up could pose a new threat to big pharma.
You may also be interested in...
Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.
The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.
Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and prioritizing investment behind multiple new launches.